Nilufer — Treatments for Silent Diseases

NILU-001

V1a AntagonistLimerence

Preclinical

Phase I

Phase II

Phase III

4.5% of adults experience limerence at any given time — 2.9M+ patients in the U.S.

Nilufer — treatments for silent diseases. NILU-001, a V1a antagonist for limerence, in Phase II.